Our Team
Scientists, physicians, and strategists united by a shared mission.
Brandon Romanek Founder & CEO
Brandon Romanek is Founder, CEO, and inventor of EPIK Biosciences’ therapeutic portfolio. He built his career in capital markets, focusing on biotech investing and analysis and has founded two publicly traded companies, gaining experience in corporate structuring and investor relations
His work on ketamine began in 2012, when few U.S. clinics existed and the compound was still widely viewed as an anesthetic. He studied its mechanisms in depth, was involved in early clinical use by 2013, and identified commercial potential in ketamine-based depression treatment before Johnson & Johnson launched Spravato.
EPIK’s combination platform—ketamine-based and DXM-based synergistic medicines for mental health, severe and chronic pain, and substance use disorders—is built from that research. Brandon leads the company’s strategy, intellectual property, fundraising, and business development.
Tyler Dunn, MD Chief Medical Officer
A board-certified anesthesiologist with advanced training from Mayo Clinic Arizona, one of the nation’s leading academic medical centers. Dr. Dunn brings clinical expertise in pain management, sedation pharmacology, and perioperative medicine. He serves as a senior advisor to Pacira Biosciences (NASDAQ: PCRX), a publicly traded pharmaceutical company specializing in non-opioid post-surgical pain management — directly relevant to EPIK’s therapeutic mission. Dr. Dunn oversees EPIK’s clinical strategy, formulation science, and the Labcorp development program.
David Wiegmann, MD Chief Clinical Officer
A board-certified anesthesiologist, published researcher, and multi-institution clinical investigator with a proven track record of designing clinical protocols and driving measurable patient outcomes. Dr. Wiegmann’s research background spans pain management, neuroscience pharmacology, and acute care and pain medicine. He brings direct experience in the clinical applications EPIK is targeting — including chronic pain, depression, and substance use disorders. Dr. Wiegmann leads EPIK’s clinical development strategy and will oversee clinical trial design and execution as the company advances toward IND submission.